OncoMatch/Clinical Trials/NCT07188896
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Is NCT07188896 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Fianlimab and Ipilimumab for advanced renal cell carcinoma (arcc).
Treatment: Fianlimab · Ipilimumab · Nivolumab · Cemiplimab — This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage IV
Prior therapy
Cannot have received: systemic therapy
Prior systemic therapy against renal cell carcinoma in the neo/adjuvant or metastatic setting
Lab requirements
Blood counts
Demonstrate adequate organ function as defined in the protocol
Kidney function
Demonstrate adequate organ function as defined in the protocol
Liver function
Demonstrate adequate organ function as defined in the protocol
Demonstrate adequate organ function as defined in the protocol. All screening labs to be obtained within 14 days prior to registration.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Vanderbilt-Ingram Cancer Center · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify